Clinical and experimental neuroprotection in neurodegenerative diseases is a therapeutic option for the future of amyotrophic lateral sclerosis (ALS). Preface

J Neurol. 2000 Dec:247 Suppl 6:VI/1. doi: 10.1007/BF03161073.
No abstract available

Publication types

  • Introductory Journal Article

MeSH terms

  • Amyotrophic Lateral Sclerosis / drug therapy*
  • Amyotrophic Lateral Sclerosis / genetics
  • Amyotrophic Lateral Sclerosis / pathology
  • Animals
  • Disease Models, Animal
  • Humans
  • Neurodegenerative Diseases / drug therapy*
  • Neurodegenerative Diseases / pathology
  • Neuroprotective Agents / therapeutic use*
  • Superoxide Dismutase / genetics

Substances

  • Neuroprotective Agents
  • Superoxide Dismutase